Stock Analysis

HealthEquity Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

NasdaqGS:HQY
Source: Shutterstock

HealthEquity (NASDAQ:HQY) Third Quarter 2025 Results

Key Financial Results

  • Revenue: US$300.4m (up 21% from 3Q 2024).
  • Net income: US$5.70m (down 61% from 3Q 2024).
  • Profit margin: 1.9% (down from 5.9% in 3Q 2024).
  • EPS: US$0.065 (down from US$0.17 in 3Q 2024).
earnings-and-revenue-growth
NasdaqGS:HQY Earnings and Revenue Growth December 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

HealthEquity Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 3.6%. Earnings per share (EPS) missed analyst estimates by 75%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 5.9% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with HealthEquity, and understanding it should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if HealthEquity might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.